Heinemann, Volker
von Weikersthal, Ludwig Fischer
Decker, Thomas
Kiani, Alexander
Kaiser, Florian
Al-Batran, Salah-Edin
Heintges, Tobias
Lerchenmüller, Christoph
Kahl, Christoph
Seipelt, Gernot
Kullmann, Frank
Moehler, Markus
Scheithauer, Werner
Held, Swantje
Miller-Phillips, Lisa
Modest, Dominik Paul
Jung, Andreas
Kirchner, Thomas
Stintzing, Sebastian
Funding for this research was provided by:
Merck KGaA
Article History
Received: 24 April 2020
Revised: 17 September 2020
Accepted: 8 October 2020
First Online: 6 November 2020
Ethics approval and consent to participate
: The protocol and informed consent forms were approved by the ethic committee of the Medical Faculty of the Ludwig-Maximilians-University (reference number: 370-06). Informed consent was obtained from all subjects prior to participating in the study. The study was conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: All authors had access to the data published in this paper. Data have been uploaded to the Pharmnet.bund online platform of the German federal department of health (ExternalRef removed).
: Dr. Heinemann reported financial relationships with Merck-Serono, Roche, Servier, Sirtex, Bristol-Myers Squibb, Merck Sharp & Dohme, Bayer, Boehringer-Ingelheim and Eli Lilly and Company. Dr. Jung reported financial relationships with Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Roche, Novartis and Merck-Serono. Dr. Kiani reported receiving honoraria from Merck & Co, Roche and Amgen. Dr. Kirchner reported financial relationships with Merck-Serono, AstraZeneca, Amgen, Merck Sharp & Dohme, Novartis, Pfizer and Roche. Dr. Kullmann reported financial relationships with Roche and Celgene. Dr. Modest reported financial relationships with Merck-Serono, Roche, Servier, Sirtex, Bristol-Myers Squibb, Merck Sharp & Dohme, Bayer, Boehringer-Ingelheim and Eli Lilly and Company. Dr. Moehler reported financial relationships with Amgen, Bristol-Myers Squibb, Merck Sharp & Dohme, Merck-Serono, Eli Lilly and Company, Dr. Falk Pharma GmbH, Pfizer and Roche. Dr. Stintzing reported receiving honoraria from Amgen, Merck-Serono, Pierre-Fabre, Servier, Roche, Sanofi, Bayer, Takeda and Eli Lilly and Company. Dr. von Weikersthal reported receiving honoraria from Roche, Novartis and Genzyme. No other disclosures were reported.
: This work was supported by grants from Pfizer GmbH, Germany, and Merck KGaA, Darmstadt, Germany. The funding sources had a role in the design and conduct of the study, and in the collection, management, analysis and interpretation of the data. Prior to 2009, cetuximab was supplied by Merck-Serono GmbH, an affiliate of Merck KGaA, Darmstadt, Germany. Merck KGaA reviewed the paper for medical accuracy only and had no role in the decision to submit the paper for publication. The authors are fully responsible for the content of this paper, and the views and opinions described in the publication solely reflect those of the authors. Open access funding enabled and organized by Projekt DEAL.